Drug Trial Radar · NCT05479812
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Aug 15, 2022
Primary completion
Apr 22, 2026
Study completion Apr 22, 2026
Sponsor
- Lead sponsor
- Werewolf Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Conditions
- Metastatic Solid Tumor
- Advanced Solid Tumor
Interventions
WTX-124Drug
Investigation Product Monotherapy
pembrolizumabDrug
Investigation Product in combination with approved therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapyTime frame: 4 weeks
- Incidence of treatment emergent adverse events in monotherapy and combination therapyTime frame: 24 months
- Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapyTime frame: 24 months
- Dose Expansion - Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapyTime frame: 4 weeks
- Dose Expansion - Incidence of treatment emergent adverse events in monotherapy and combination therapyTime frame: 24 months
- Dose Expansion - Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapyTime frame: 24 months
- Dose Expansion - Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapyTime frame: 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
Moffitt Cancer Center
Tampa, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Minnesota Oncology Hematology, P.A.
Maple Grove, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Care
Buffalo, New York
Westchester Medical Center
Hawthorne, New York
Providence Cancer Institute Franz Clinic
Portland, Oregon
Texas Oncology - Austin Midtown
Austin, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
NEXT Oncology
Houston, Texas
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.